文献速递湿疹皮炎与荨麻疹

乌帕替尼治疗青少年中重度特应性皮炎:3项3期随机临床试验76周分析

Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks.
PubMed 文献 · JAMA Dermatol · 2024-01-01

该分析基于Measure Up 1、Measure Up 2和AD Up三项双盲安慰剂对照3期试验,评估乌帕替尼15mg或30mg治疗青少年中重度特应性皮炎至76周的疗效与安全性。共纳入542例青少年,第76周时EASI-75应答率在15mg组为84.4%-89.1%,30mg组为82.7%-96.1%,vIGA-AD 0/1和WP-NRS改善≥4分亦维持或改善,不良事件谱与已知一致,未见新信号。

要点

  • 乌帕替尼15mg和30mg在青少年中重度AD中76周疗效持续,EASI-75应答率高。
  • 瘙痒改善(WP-NRS≥4分)和vIGA-AD 0/1应答至76周维持或提升。
  • 长期安全性符合已知特征,疱疹感染和肌酸激酶升高发生率低,无新信号。

核心结论

  • 乌帕替尼长期治疗青少年中重度AD显示有利的风险获益比,疗效应答持续至76周。

研究设计与样本

  • 三项正在进行的双盲、安慰剂对照3期随机临床试验(Measure Up 1、Measure Up 2、AD Up)汇总分析。
  • 纳入542例12-17岁中重度AD青少年,随机1:1:1接受乌帕替尼15mg、30mg或安慰剂每日一次,第16周安慰剂组重随机至乌帕替尼15mg或30mg。
  • 数据收集自2018年8月至2022年4月,分析自2022年6月至2023年9月。

主要发现

  • 第76周,Measure Up 1、Measure Up 2和AD Up试验中乌帕替尼15mg组EASI-75应答率分别为89.1%、84.4%、87.8%,30mg组分别为96.1%、93.6%、82.7%。
  • vIGA-AD 0/1和WP-NRS改善≥4分的疗效至76周维持或改善。
  • 长期安全性:疱疹感染发生率分别为4.0、1.9、1.1事件/100患者年;肌酸激酶升高分别为11.6、11.0、7.1事件/100患者年,未见新信号。

关键数值与推荐

  • EASI-75:第76周乌帕替尼15mg组在三项试验中分别为89.1%、84.4%、87.8%;30mg组分别为96.1%、93.6%、82.7%。
  • vIGA-AD 0/1和WP-NRS≥4分改善至76周维持或改善(原文未报告具体数值)。
  • 疱疹感染:4.0、1.9、1.1事件/100患者年(对应Measure Up 1、Measure Up 2、AD Up)。
  • 肌酸激酶升高:11.6、11.0、7.1事件/100患者年(对应Measure Up 1、Measure Up 2、AD Up)。

临床怎么用

  • 乌帕替尼15mg或30mg可作为青少年中重度AD的长期治疗选择,76周疗效持续。
  • 治疗期间需关注疱疹感染和肌酸激酶升高,但发生率较低且与已知安全性一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The Measure Up 1, Measure Up 2, and AD Up studies demonstrated the efficacy and adverse events of upadacitinib through 52 weeks in adults and adolescents with atopic dermatitis (AD); however, longer-term outcomes (longer than 1 year) in adolescents have not previously been available. OBJECTIVE: To evaluate the efficacy and adverse events of upadacitinib in adolescent patients with moderate to severe AD through 76 weeks. DESIGN, SETTING, AND PARTICIPANTS: The Measure Up 1, Measure Up 2, and AD Up trials are ongoing double-blind, placebo-controlled phase 3 randomized clinical trials including adolescents (aged 12 to 17 years) with moderate to severe AD. Data were collected from August 2018 to April 2022, and data were analyzed from June 2022 to September 2023. INTERVENTIONS: Adolescents were randomized 1:1:1 to receive once-daily oral upadacitinib, 15 mg; upadacitinib, 30 mg; or placebo, either alone (Measure Up 1 and Measure Up 2 trials) or with topical corticosteroids (AD Up). At week 16, placebo-treated patients were rerandomized to receive upadacitinib, 15 mg, or upadacitinib, 30 mg, daily. MAIN OUTCOMES AND MEASURES: Coprimary end points assessing efficacy included achievement of 75% reduction or more in the Eczema Area and Severity Index Score (EASI-75) from baseline, Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear (0) or almost clear (1) with 2 grades or more of improvement, and Worst Pruritus Numerical Rating Scale (WP-NRS) improvement of 4 points or greater through week 76 for participants with a WP-NRS score of 4 points or higher at baseline. RESULTS: From all studies, 542 adolescents were included; of these, 284 (52.4%) were female. At week 76, among patients in the Measure Up 1, Measure Up 2, and AD Up trials, EASI-75 was achieved by 89.1%, 84.4%, and 87.8% of adolescents taking upadacitinib, 15 mg, respectively, and by 96.1%, 93.6%, and 82.7% of adolescents taking upadacitinib, 30 mg, indicating maintenance or improvement of EASI-75 across 76 weeks with upadacitinib. Efficacy measured by achievement of vIGA-AD score of 0 or 1 and WP-NRS improvement of 4 points or more from baseline was similarly maintained or improved through week 76 for adolescents taking upadacitinib, 15 mg or 30 mg. Long-term outcomes in Measure Up 1, Measure Up 2, and AD Up participants were consistent with the known adverse event profile of upadacitinib (herpetic infection: 4.0, 1.9, and 1.1 events per 100 patient-years, respectively; creatine kinase elevation: 11.6, 11.0, and 7.1 events per 100 patient-years); no new signals were observed with either dose. CONCLUSIONS AND RELEVANCE: In this study assessing 3 randomized clinical trials, long-term treatment of adolescents with moderate to severe AD with upadacitinib demonstrated a favorable benefit-risk profile, with sustained efficacy responses through 76 weeks. TRIAL REGISTRATIONS: Measure Up 1 trial: ClinicalTrials.gov Identifier: NCT03569293; Measure Up 2 trial: NCT03607422; AD Up trial: NCT03568318.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Paller AS, Mendes-Bastos P, Siegfried E, et al. Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks. JAMA Dermatol. 2024. PMID: 39441580. doi:10.1001/jamadermatol.2024.3696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。